XML 58 R46.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Liability Related to Sale of Future Royalties (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 12 Months Ended
Jan. 31, 2023
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Royalty Revenue Monetization [Abstract]        
Proceeds from sale of future royalties in January 2023   $ 0 $ 500,000  
Issuance costs related to sale of future royalties   0 (10,434)  
Royalty payments to Royalty Pharma   (6,623) 0  
Interest expense related to sale of future royalties   17,806 $ 15,363  
Net liability related to sale of future royalties   525,072   $ 513,736
Royalty Purchase Agreement [Member]        
Royalty Revenue Monetization [Abstract]        
Upfront payment received $ 500,000      
Maximum amount of payments receivable for additional milestones   $ 625,000    
Effective interest rate   13.50%    
Proceeds from sale of future royalties in January 2023 $ 500,000      
Issuance costs related to sale of future royalties       (10,434)
Royalty payments to Royalty Pharma   $ (6,623)   (44,628)
Interest expense related to sale of future royalties   17,806   68,238
Amortization of issuance costs related to sale of future royalties   153   560
Net liability related to sale of future royalties   525,072   $ 513,736
Royalty Purchase Agreement [Member] | SPINRAZA [Member]        
Royalty Revenue Monetization [Abstract]        
Maximum amount of annual sales on which royalty payments are paid   $ 1,500,000    
Royalty Purchase Agreement [Member] | SPINRAZA [Member] | Minimum [Member]        
Royalty Revenue Monetization [Abstract]        
Percentage of royalty payments paid on annual sales of medicine   25.00%    
Maximum royalty payments made before royalty interest reverts back   $ 475,000    
Royalty Purchase Agreement [Member] | SPINRAZA [Member] | Maximum [Member]        
Royalty Revenue Monetization [Abstract]        
Percentage of royalty payments paid on annual sales of medicine   45.00%    
Maximum royalty payments made before royalty interest reverts back   $ 550,000    
Royalty Purchase Agreement [Member] | Pelacarsen [Member]        
Royalty Revenue Monetization [Abstract]        
Percentage of royalty payments paid on annual sales of medicine   25.00%